The dual SRC-ABL inhibitors in Ph plus acute lymphoblastic leukemia to enhance synergy between targeted BCR-ABL and BCL-2 inhibitors.

被引:0
|
作者
Leonard, Jessica Taft
Spurgeon, Stephen Edward Forbes
Traer, Elie A.
Hayes-Lattin, Brandon M.
Loriaux, Marc
Tyner, Jeffrey
Druker, Brian J.
Chang, Bill H.
机构
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA
[3] Doernbecher Childrens Hosp, Portland, OR USA
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
7073
引用
收藏
页数:1
相关论文
共 50 条
  • [11] Combining blinatumomab with targeted therapy for BCR-ABL mutant relapsed/refractory acute lymphoblastic leukemia
    Hanif, Ahmad
    Wang, Eunice S.
    Thompson, James E.
    Baron, Jeffrey I.
    Walsh, Mark D.
    Griffiths, Elizabeth A.
    LEUKEMIA & LYMPHOMA, 2018, 59 (08) : 2011 - 2013
  • [12] Dual kinase Src-Abl inhibitors: An emerging class of targeted agents with activity in hematologic malignancy and solid tumors
    Wright, JJ
    ANNALS OF ONCOLOGY, 2006, 17 : 24 - 24
  • [13] Inhibition of mitochondrial respiration synergizes with tyrosine kinase inhibitors to eliminate Bcr-Abl plus leukemia
    Alvarez-Calderon, Francesca
    Gregory, Mark A.
    DeGregori, James
    CANCER RESEARCH, 2011, 71
  • [14] Discordance between Next Generation Sequencing and BCR-ABL PCR Measurable Residual Disease in Adult Patients with Ph plus Acute Lymphoblastic Leukemia
    Dekker, Simone E.
    Sabile, Jean
    Dasilva, Brandon
    Saygin, Caner
    Schwartz, Marc
    Raman, Hari S.
    Kaempf, Andy
    Luskin, Marlise R.
    Patel, Anand Ashwin
    Muffly, Lori S.
    Leonard, Jessica T.
    BLOOD, 2023, 142
  • [15] Characterization of BCR-ABL Specific CD4+T Cells and Their Role in Controlling Ph plus Acute Lymphoblastic Leukemia
    Tracy, Sean I.
    Hekim, Can
    Farrar, Michael
    BLOOD, 2019, 134
  • [16] PROGNOSTIC RELEVANCE AND KINETICS OF P-LOOP MUTATIONS IN PATIENTS WITH BCR-ABL/PH plus ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)
    Pfeifer, H.
    Stracke, S.
    Gassmann, W.
    Kaufmann, M.
    Stadler, M.
    Staib, P.
    Kaun, S.
    Link, H.
    Giagounidis, A.
    Rummel, M.
    Horst, H.
    Stelljes, M.
    Kubuschok, K.
    Starck, M.
    Arnold, R.
    Schwerdtfeger, R.
    Junghanss, C.
    Beelen, D. Wilhelm
    Karthaus, M.
    Hertenstein, B.
    Hindahl, H.
    Hoelzer, D.
    Serve, H.
    Ottmann, O.
    HAEMATOLOGICA, 2013, 98 : 257 - 258
  • [17] Simultaneous targeting of SRC and BCR-ABL kinases by BMS354825 cures Ph+ acute lymphoblastic leukemia in mice.
    Li, SG
    Hu, YG
    Swerdlow, SJ
    Lee, FY
    BLOOD, 2004, 104 (11) : 545A - 546A
  • [18] MODELING RESISTANCE TO TYROSINE KINASE INHIBITORS IN TEL/ABL plus ACUTE LYMPHOBLASTIC LEUKEMIA
    Zimmermannova, O.
    Zuna, J.
    Machova, K.
    Lizcova, L.
    Zemanova, Z.
    Falkenburg, J.
    Harvey, R.
    Chen, I. M.
    Willman, C. L.
    Trka, J.
    Zaliova, M.
    HAEMATOLOGICA, 2014, 99 : 271 - 272
  • [19] Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML
    Benjamini, Ohad
    Kantarjian, Hagop M.
    O'Brien, Susan
    Thomas, Deborah
    Ravandi, Farhad
    Jain, Preetesh
    Pierce, Sherry
    Borthakur, Gautam
    Kadia, Tapan M.
    Jabbour, Elias
    Estrov, Zeev
    Luthra, Rajyalakshmi
    Cortes, Jorge E.
    BLOOD, 2013, 122 (21)
  • [20] BCR-ABL translocation as a favorable prognostic factor in elderly patients with acute lymphoblastic leukemia in the era of potent tyrosine kinase inhibitors
    Byun, Ja Min
    Koh, Youngil
    Shin, Dong-Yeop
    Kim, Inho
    Yoon, Sung-Soo
    Lee, Jeong-Ok
    Bang, Soo-Mee
    Kim, Ki Hwan
    Jung, Sung-Hoon
    Lee, Won Sik
    Park, Yong
    Jang, Jun Ho
    Han, Jae Joon
    Yhim, Ho-Young
    Kim, Dae Sik
    Lee, Yoo Jin
    Lee, Hyewon
    Choi, Yun-Suk
    Lee, Seok
    HAEMATOLOGICA, 2017, 102 (05) : E187 - E190